Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.03, FiscalAI reports.
Tvardi Therapeutics Stock Up 2.2%
Tvardi Therapeutics stock traded up $0.03 during midday trading on Friday, reaching $1.18. The stock had a trading volume of 74,674 shares, compared to its average volume of 379,804. Tvardi Therapeutics has a 12 month low of $0.77 and a 12 month high of $5.69. The firm’s 50-day moving average price is $1.23 and its 200 day moving average price is $2.60. The firm has a market capitalization of $15.74 million, a PE ratio of -0.42 and a beta of 0.37.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in TVRD. GSA Capital Partners LLP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at $34,000. Susquehanna International Group LLP bought a new position in shares of Tvardi Therapeutics in the second quarter worth $63,000. Finally, BlackRock Inc. purchased a new stake in shares of Tvardi Therapeutics in the second quarter worth $181,000. Institutional investors own 44.66% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have weighed in on TVRD. BTIG Research decreased their price target on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, October 2nd. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. Wall Street Zen downgraded Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, November 1st. Finally, Chardan Capital initiated coverage on Tvardi Therapeutics in a research report on Tuesday, October 20th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.40.
Read Our Latest Analysis on Tvardi Therapeutics
Tvardi Therapeutics Company Profile
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.
Featured Stories
- Five stocks we like better than Tvardi Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
